Pacific Edge (ASX:PEB) Valuation Rank


ASX:PEB Pacific Edge Ltd ASX:PEB
42 GF Score
Price A$0.25
GF Value A$0.05
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Pacific Edge Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Pacific Edge Valuation Rank Related Terms

ASX:PEB
42GF Score
Pacific Edge Ltd ASX:PEB
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Pacific Edge (ASX:PEB) Overvalued in 2026?

Based on GuruFocus' analysis, Pacific Edge stock appears to be overvalued. The current stock price of A$0.25 is trading 390% above its estimated GF Value™ of A$0.05. GuruFocus considers Pacific Edge to be Significantly Overvalued.

Key valuation signals for ASX:PEB:

  • Valuation Rank:
  • GF Value™: A$0.05 vs. price of A$0.25 (390% above fair value)
  • GF Score™: 42/100 with 7 warning signs

No single metric tells the full story. See the ASX:PEB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pacific Edge Business Description

Address 87 Saint David Street, P.O. Box 56, Dunedin, STL, NZL, 9016
Pacific Edge Ltd is a New Zealand-based company involved in researching, developing, and commercialising new diagnostic and prognostic tools for the early detection and management of cancers. It manages and operates the laboratories used for the detection of bladder cancer. It operates in two segments: Commercial, which includes sales, marketing, laboratory, and support operations to run the commercial businesses internationally; and Research, which is into research and development of diagnostic and prognostic products for human cancer. The commercial segment contributes to the majority of the revenue. Pacific Edge has a product in the marketplace called Cxbladder. Its geographical segments are the United States, which generates maximum revenue, New Zealand, and the Rest of the World.
42GF Score

Get the complete analysis for ASX:PEB

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.25
Price
A$0.05
GF Value